The US Food and Drug Administration (FDA) has removed several web pages dedicated to improving diversity in clinical trials, sparking concerns among public health advocates. This decision coincides with a broader trend influenced by recent political transitions, particularly the executive order banning diversity, equity, and inclusion (DEI) initiatives. Critics argue that the removal of these resources undermines efforts to promote equitable participation in clinical research, especially in cancer studies. The agency’s actions raise questions about the future of DEI work within its framework, indicating a potentially significant shift in its approach to ensuring diverse representation in medical trials.